<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486640</url>
  </required_header>
  <id_info>
    <org_study_id>18016</org_study_id>
    <secondary_id>BF1502</secondary_id>
    <nct_id>NCT02486640</nct_id>
  </id_info>
  <brief_title>Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon</brief_title>
  <acronym>BETAPREDICT</acronym>
  <official_title>BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate potential predictors of adherence by investigating a
      representative cohort of MS patients in Germany treated with Betaferon
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 8, 2015</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance to therapy (%)</measure>
    <time_frame>12 months</time_frame>
    <description>Compliance (%) = ((expected # of treatment days during observation period - missed # of treatment days during observation period)/(expected # of treatment days during observation period))*100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence of therapy (Yes or No)</measure>
    <time_frame>12 months</time_frame>
    <description>Persistence is defined as patients continuing (&quot;persisting&quot;) their medication (regardless of the frequency of intake)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall adherence to therapy (Yes or No)</measure>
    <time_frame>12 months</time_frame>
    <description>Patients will be defined as being adherent to therapy if they fulfill the following criteria: a. They have been at least 80% compliant, i.e. injected ≥80% of the expected Betaferon dosages and b. They have not dropped out of the study prior to the time of evaluation (i.e. they did not stop Betaferon treatment for any reason including switching to another medication prior to the time of evaluation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with the BETACONNECT autoinjector, recorded by the patient questionnaire</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Betaferon treatment is associated with: depression, health related quality of life, coping mechanisms, self-management mechanisms, social support, fatigue, and cognition. (Yes or No)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Betaferon treatment is associated with number of relapses (Yes or No)</measure>
    <time_frame>12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Betaferon treatment is associated with EDSS change (Yes or No)</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>EDSS (Expanded Disability Status Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Betaferon treatment is associated with utilities of treatment, recorded by the EQ5-D quality of life questionnaire (Yes or No)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">162</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Betaferon</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1b (Betaferon, BAY86-5046)</intervention_name>
    <description>Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector.</description>
    <arm_group_label>Betaferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Betaconnect Autoinjector</intervention_name>
    <description>Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector.</description>
    <arm_group_label>Betaferon</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of patients with relapsing remitting multiple sclerosis
        (RRMS) or patients with a clinically isolated syndrome (CIS) who are treated with Betaferon
        or will be treated with Betaferon according to the attending physician's decision and for
        whom the patient and the physician have agreed to use the BETACONNECT device
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically
             isolated syndrome.

          -  Patients must be on treatment with Betaferon or the decision to treat patients with
             Betaferon has been made by the attending physician.

          -  Patients must be using the BETACONNECTTM auto-injector for Betaferon application.

          -  Written informed consent must be obtained.

        Exclusion Criteria:

          -  Patients receiving any other disease modifying drug.

          -  Contraindications of Betaferon described in the Summary of Product Characteristics.

          -  Patients participating in any other clinical or noninterventional study, evaluating MS
             therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RRMS, CIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

